Tag: Immune Checkpoint Inhibitor

Cutaneous immune-related AEs may predict toxicities in ICI-treated patients

Presented By
Elle Kim, John Hopkins University, MD, USA
Conference
AAD 2025
Type
Peer-reviewed article

17 April 2025 16:19

ICI therapy does not increase mortality risk in patients with pre-existing autoimmune disease

Presented By
Dr Greg Challener, Massachusetts General Hospital, MA, USA
Conference
ACR 2024
Type
Peer-reviewed article

13 January 2025 11:09

TACITO: Does faecal microbiota transplantation improve survival in mRCC?

Presented By
Dr Gianluca Ianiro, Agostino Gemelli University Policlinic, Italy
Trial
Phase 2, TACITO
Conference
UEGW 2024
Type
Peer-reviewed article

28 November 2024 11:19

High efficacy of pembrolizumab combined with standard therapy in patients with MSS/pMMR mCRC and high immune infiltrate

Presented By
Prof. David Tougeron, Poitiers University Hospital, France
Trial
Phase 2, POCHI
Conference
ESMO GI 2024
Type
Peer-reviewed article

21 August 2024 11:31

Next-generation cell therapies for cancer: CAR-NK cells

Presented By
Dr Katy Rezvani, MD Anderson Cancer Center, TX, USA
Conference
EBMT 2023
Type
Peer-reviewed article

15 June 2023 17:20

Novel drugs and strategies around ASCT for Hodgkin lymphoma

Presented By
Dr Anna Sureda, Catalan Institute of Oncology, Spain
Conference
EBMT 2023
Type
Peer-reviewed article

15 June 2023 17:15

Immunotherapy response may be modulated by microbiome

Presented By
Dr Johannes Björk, University Medical Center Groningen, the Netherlands
Trial
PRIMM
Conference
UEGW 2022
Type
Peer-reviewed article

2 December 2022 09:48

Baseline ctDNA predicts survival in resected stage III–IV melanoma

Presented By
Prof. Georgina Long, University of Sydney, Australia
Trial
Phase 3, CheckMate 915
Conference
ESMO 2022
Type
Peer-reviewed article

16 November 2022 18:21

Tumour infiltrating lymphocytes identify patients with immunogenic triple-negative breast cancer

Presented By
Prof. Marleen Kok, Netherlands Cancer Institute, the Netherlands)
Trial
Phase 2, BELLINI
Conference
ESMO 2022
Type
Peer-reviewed article

16 November 2022 18:01

Single-cell spatial analysis can predict response to neoadjuvant immunotherapy

Presented By
Dr Giampaolo Bianchini, Ospedale San Raffaele, Italy
Trial
Phase 3, NeoTRIPaPDL1
Conference
SABCS 2021
Type
Peer-reviewed article

31 January 2022 17:48

Baseline CD8+ T-cells predict NSCLC immunotherapy safety

Presented By
Prof. Kan Wu, Zhejiang University School of Medicine, China
Conference
WCLC 2021
Type
News article

21 September 2021 15:26

Prognostic factors in immunotherapy for advanced lung cancer

Presented By
Prof. Kan Wu, Zhejiang University School of Medicine, China
Conference
WCLC 2021
Type
News article

21 September 2021 15:26

Interim results of nivolumab + rucaparib in SCLC

Presented By
Dr Aman Chauhan, University of Kentucky, KY, USA
Conference
WCLC 2021
Type
News article

21 September 2021 13:24

Immuno-oncology agents are effective in treating classic Hodgkin’s lymphoma

Presented By
Dr Marc André, Centre Hospitalier Universitaire UCL Namur, Belgium
Trial
CheckMate 205; KEYNOTE-087
Conference
EHA 2021
Type
Peer-reviewed article

5 August 2021 12:26

Promising chemo-free treatment options in r/r DLBCL

Presented By
Prof. Marco Ladetto, University del Piemonte Orientale, Italy
Trial
LOTIS-2
Conference
EHA 2021
Type
Peer-reviewed article

5 August 2021 11:17

Women at higher risk for dermatologic side effects during immunotherapy

Presented By
Mr Jordan T. Said, Harvard School of Medicine, MA, USA
Conference
AAD VMX 2021
Type
Peer-reviewed article

7 June 2021 10:44

Risk of checkpoint inhibitor-associated thromboembolic events important for cancer prognosis

Presented By
Dr Florian Moik, Medical university of Vienna, Austria
Trial
Cohort study
Conference
ISTH 2020
Type
Peer-reviewed article

8 September 2020 15:44

Immune-related AEs due to checkpoint inhibitors require care coordination

Conference
EULAR 2020
Type
Peer-reviewed article

14 August 2020 09:49

Cancer treatment with checkpoint inhibitors in RA patients?

Presented By
Dr Sabina Sandigursky, New York University Langone Medical Center, USA
Conference
ACR 2019
Type
Peer-reviewed article

4 February 2020 11:13

Five-fold increase of OS at 5 years with nivolumab vs docetaxel

Presented By
Prof. Scott Gettinger, Yale Cancer Center, USA
Trial
CheckMate 017, CheckMate 057
Conference
WCLC 2019
Type
Peer-reviewed article

8 November 2019 23:00

Skin toxicity of immune checkpoint inhibitors

Presented By
Prof. Jennifer N. Choi, Northwestern Feinberg School of Medicine, USA
Conference
WCD 2019
Type
Peer-reviewed article

26 August 2019 10:44
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com